Biogen Inc.

Symbol: BIIB

NASDAQ

222.75

USD

Market price today

  • 27.7244

    P/E Ratio

  • 0.4779

    PEG Ratio

  • 32.43B

    MRK Cap

  • 0.00%

    DIV Yield

Biogen Inc. (BIIB) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.73%

Operating Profit Margin

0.14%

Net Profit Margin

0.12%

Return on Assets

0.04%

Return on Equity

0.08%

Return on Capital Employed

0.06%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. Christopher A. Viehbacher
Full-time employees:7570
City:Cambridge
Address:225 Binney Street
IPO:1991-09-17
CIK:0000875045

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

General Outlook

When we look at how much money they make before expenses, they keep 0.733% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.141%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.122%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.044% return, is a testament to Biogen Inc.'s adeptness in optimizing resource deployment. Biogen Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.079%. Furthermore, the proficiency of Biogen Inc. in capital utilization is underscored by a remarkable 0.058% return on capital employed.

Stock Prices

Biogen Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $218.66, while its low point bottomed out at $214.7. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Biogen Inc.'s stock market.

Liquidity Ratios

Analyzing BIIB liquidity ratios reveals its financial health of the firm. The current ratio of 209.64% gauges short-term asset coverage for liabilities. The quick ratio (95.39%) assesses immediate liquidity, while the cash ratio (33.34%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio209.64%
Quick Ratio95.39%
Cash Ratio33.34%

Profitability Ratios

BIIB profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 13.82% underscores its earnings before tax deductions. The effective tax rate stands at 11.79%, revealing its tax efficiency. The net income per EBT, 88.16%, and the EBT per EBIT, 97.91%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 14.12%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin13.82%
Effective Tax Rate11.79%
Net Income per EBT88.16%
EBT per EBIT97.91%
EBIT per Revenue14.12%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.10, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding95
Days of Inventory Outstanding359
Operating Cycle435.03
Days of Payables Outstanding55
Cash Conversion Cycle380
Receivables Turnover4.79
Payables Turnover6.62
Inventory Turnover1.02
Fixed Asset Turnover2.58
Asset Turnover0.36

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 11.33, and free cash flow per share, 8.85, depict cash generation on a per-share basis. The cash per share value, 7.40, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.17, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share11.33
Free Cash Flow per Share8.85
Cash per Share7.40
Operating Cash Flow Sales Ratio0.17
Free Cash Flow to Operating Cash Flow Ratio0.78
Cash Flow Coverage Ratio0.25
Short Term Coverage Ratio6.58
Capital Expenditure Coverage Ratio4.56
Dividend Paid and Capex Coverage Ratio4.56

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 24.62%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.43, we discern the balance between debt and equity financing. The long-term debt to capitalization, 29.25%, and total debt to capitalization, 30.07%, ratios shed light on its capital structure. An interest coverage of 5.33 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio24.62%
Debt Equity Ratio0.43
Long Term Debt to Capitalization29.25%
Total Debt to Capitalization30.07%
Interest Coverage5.33
Cash Flow to Debt Ratio0.25
Company Equity Multiplier1.75

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 67.97, provides a glimpse into top-line earnings distributed across each share. Net income per share, 8.02, reflects the portion of profit attributed to each share. The book value per share, 102.28, represents the net asset value distributed per share, while the tangible book value per share, 1.50, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share67.97
Net Income Per Share8.02
Book Value Per Share102.28
Tangible Book Value Per Share1.50
Shareholders Equity Per Share102.28
Interest Debt Per Share52.42
Capex Per Share-2.15

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -3.32%, indicates top-line expansion, while the gross profit growth, -7.51%, reveals profitability trends. EBIT growth, -44.11%, and operating income growth, -44.11%, offer insights into operational profitability progression. The net income growth, -61.89%, showcases bottom-line expansion, and the EPS growth, 590.36%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-3.32%
Gross Profit Growth-7.51%
EBIT Growth-44.11%
Operating Income Growth-44.11%
Net Income Growth-61.89%
EPS Growth590.36%
EPS Diluted Growth597.65%
Weighted Average Shares Growth-100.00%
Weighted Average Shares Diluted Growth-100.00%
Operating Cash Flow Growth-100.00%
Free Cash Flow Growth-75.73%
10-Year Revenue Growth per Share-100.00%
5-Year Revenue Growth per Share-100.00%
3-Year Revenue Growth per Share-100.00%
10-Year Operating CF Growth per Share-100.00%
5-Year Operating CF Growth per Share-100.00%
3-Year Operating CF Growth per Share-100.00%
10-Year Net Income Growth per Share-100.00%
5-Year Net Income Growth per Share-100.00%
3-Year Net Income Growth per Share-100.00%
10-Year Shareholders Equity Growth per Share-100.00%
5-Year Shareholders Equity Growth per Share-100.00%
3-Year Shareholders Equity Growth per Share-100.00%
10-Year Dividend per Share Growth per Share-100.00%
3-Year Dividend per Share Growth per Share-100.00%
Book Value per Share Growth-100.00%
R&D Expense Growth10.35%
SGA Expenses Growth6.08%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 43,732,319,000, captures the company's total value, considering both debt and equity. Income quality, 1.33, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.25, gauges operational efficiency, while the research and development to revenue, 25.03%, highlights investment in innovation. The ratio of intangibles to total assets, 54.32%, indicates the value of non-physical assets, and capex to operating cash flow, -20.13%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value43,732,319,000
Income Quality1.33
Sales General and Administrative to Revenue0.25
Research and Development to Revenue25.03%
Intangibles to Total Assets54.32%
Capex to Operating Cash Flow-20.13%
Capex to Revenue-3.17%
Capex to Depreciation-62.93%
Stock-Based Compensation to Revenue2.69%
Graham Number135.89
Return on Tangible Assets9.47%
Graham Net Net-56.37
Working Capital3,425,000,000
Tangible Asset Value217,200,000
Net Current Asset Value-5,186,100,000
Average Receivables2,118,200,000
Average Payables447,400,000
Average Inventory1,935,900,000
Days Sales Outstanding78
Days Payables Outstanding58
Days of Inventory On Hand364
ROIC5.25%
ROE0.08%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.13, and the price to book ratio, 2.13, reflect the market's valuation relative to the company's book value. The price to sales ratio, 3.39, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 25.25, and price to operating cash flows, 19.66, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.13
Price to Book Ratio2.13
Price to Sales Ratio3.39
Price Cash Flow Ratio19.66
Price Earnings to Growth Ratio0.48
Enterprise Value Multiple11.08
Price Fair Value2.13
Price to Operating Cash Flow Ratio19.66
Price to Free Cash Flows Ratio25.25
Price to Tangible Book Ratio2.53
Enterprise Value to Sales4.45
Enterprise Value Over EBITDA16.83
EV to Operating Cash Flow28.27
Earnings Yield3.10%
Free Cash Flow Yield3.30%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Biogen Inc. (BIIB) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 27.724 in 2024.

What is the ticker symbol of Biogen Inc. stock?

The ticker symbol of Biogen Inc. stock is BIIB.

What is company IPO date?

IPO date of Biogen Inc. is 1991-09-17.

What is company current share price?

Current share price is 222.750 USD.

What is stock market cap today?

The market cap of stock today is 32431731750.000.

What is PEG ratio in 2024?

The current 0.478 is 0.478 in 2024.

What is the number of employees in 2024?

In 2024 the company has 7570.